en · de · es · fr · pt
semax-notes.peptides6908.com › Guide › Semax Background And Chemistry — Research Overview

Semax Background And Chemistry — Research Overview

By Editorial Desk · published 2025-09-22 · last reviewed 2025-10-14 · Guide

Semax comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2025-10-14. Numbers and descriptions here follow the published literature rather than marketing material.

Semax Background and Chemistry

The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.

Semax 的分子背景与结构

该化合物于二十世纪八十年代在俄罗斯被开发,相关工作由俄罗斯科学院分子遗传学研究所的研究团队主导。开发目标并非复制 ACTH 的完整激素活性,而是寻找保留其神经作用方向、同时去除促肾上腺皮质激素释放效应的短肽片段。研究记录显示,这一方向促成了多个相关短肽的合成与筛选,而 Semax 是其中被研究最广泛的一个。当地文献常以 Семакс 这一名称指代它。

研究兴趣主要集中在神经营养因子相关的路径上,包括脑源性神经营养因子与神经生长因子的表达变化。部分实验报告称在特定条件下观察到这些因子的水平上升,但具体信号通路和剂量依赖关系仍未完全厘清。多数公开数据来自细胞模型和动物实验,人体对照研究数量有限。因此,该化合物的作用机制在文献中属于活跃讨论,而非已经确立的定论。

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SContains one methionine sulfur atom
Molecular massApproximately 814 DaConsistent with a seven-residue peptide
AppearanceWhite to off-white powderTypical lyophilized form
SolubilityFreely soluble in waterAlso soluble in dimethyl sulfoxide
Typical storage-20 °C, desiccatedLimits methionine oxidation

Background and Development History

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

Related pages on this site

Semax Peptide Structure and Origin

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.

Background and Development

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Semax Peptide Background and Identity

Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.

Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.

Semax is a synthetic seven-amino-acid peptide whose sequence extends the ACTH(4-10) fragment with a C-terminal proline-glycine-proline tripeptide. The commonly cited sequence is Met-Glu-His-Phe-Pro-Gly-Pro, giving a molecular formula near C37H51N9O10S and a molecular weight close to 813.9 g/mol. It belongs to the broader class of synthetic ACTH fragments studied for central nervous system effects rather than for adrenal steroid stimulation. In practice the material appears as a lyophilized white powder for laboratory work or as a dilute saline solution in clinical settings.

Further detail

Food and biological process engineering is a discipline concerned with applying principles of engineering to the fields of food production and distribution and biology. It is a broad field, with workers fulfilling a variety of roles ranging from design of food processing equipment to genetic modification of organisms. In some respects it is a combined field, drawing from the disciplines of food science and biological engineering to improve the Earth's food supply. Creating, processing, and storing food to support the world's population requires extensive interdisciplinary knowledge. Notably, there are many biological engineering processes within food engineering to manipulate the multitude of organisms involved in our complex food chain. Food safety in particular requires biological study to understand the microorganisms involved and how they affect humans. However, other aspects of food engineering, such as food storage and processing, also require extensive biological knowledge of both the food and the microorganisms that inhabit it. This food microbiology and biology knowledge becomes biological engineering when systems and processes are created to maintain desirable food properties and microorganisms while providing mechanisms for eliminating the unfavorable or dangerous ones.

== Marine plastic waste == Thailand was ranked sixth of 20 nations (1=biggest contributor; 20=lowest contributor) for its contribution to marine plastic waste in 2010. Other ASEAN nations were ranked: Indonesia, 2; Philippines, 3; Vietnam, 4; Malaysia, 8; Myanmar, 17. Thailand's contribution to sea debris has reportedly risen from 400,000 tonnes in 1967 to one million tonnes in 2019.

The difficulty that has been encountered in finding contributory alleles for complex diseases and in replicating positive associations suggests that many complex diseases involve numerous variants rather than a moderate number of alleles, and the influence of any given variant may depend in critical ways on the genetic and environmental background. If many alleles are required to increase susceptibility to a disease, the odds are low that the necessary combination of alleles would become concentrated in a particular group purely through drift.

== Antideuterium and the antideuteron == An antideuteron is the antimatter counterpart of the deuteron, consisting of an antiproton and an antineutron. The antideuteron was first produced in 1965 at the Proton Synchrotron at CERN and the Alternating Gradient Synchrotron at Brookhaven National Laboratory. A complete atom, with a positron orbiting the nucleus, would be called antideuterium, but as of 2019 antideuterium has not yet been created. The symbol used for antideuterium is D, that is, D with an overbar.

Sources: en.wikipedia.org

Background from the literature

Although cadmium usually has an oxidation state of +2, it also exists in the +1 state. Cadmium and its congeners are not always considered transition metals, in that they do not have partly filled d or f electron shells in the elemental or common oxidation states. Cadmium burns in air to form brown amorphous cadmium oxide (CdO); the crystalline form of this compound is a dark red which changes color when heated, similar to zinc oxide. Hydrochloric acid, sulfuric acid, and nitric acid dissolve cadmium by forming cadmium chloride (CdCl2), cadmium sulfate (CdSO4), and cadmium nitrate (Cd(NO3)2) respectively. The oxidation state +1 can be produced by dissolving cadmium in a mixture of cadmium chloride and aluminium chloride, forming the Cd2+2 cation as cadmium(I) tetrachloroaluminate, which is similar to the Hg2+2 cation in mercury(I) chloride.

However, not all were convinced by Fermi's analysis of his results, though he would win the 1938 Nobel Prize in Physics for his "demonstrations of the existence of new radioactive elements produced by neutron irradiation, and for his related discovery of nuclear reactions brought about by slow neutrons". The German chemist Ida Noddack notably suggested in 1934 that instead of creating a new, heavier element 93, that "it is conceivable that the nucleus breaks up into several large fragments." However, the quoted objection comes some distance down, and was but one of several gaps she noted in Fermi's claim. Although Noddack was a renowned analytical chemist, she lacked the background in physics to appreciate the enormity of what she was proposing.

=== Off-label drugs === Acetylcholinesterase inhibitors (e.g., donepezil, galantamine, rivastigmine) – cognitive impairment in Parkinson's disease Anticholinergics (antimuscarinics/muscarinic acetylcholine receptor antagonists) (e.g., trihexyphenidyl, procyclidine, diphenhydramine, benztropine, ethopropazine, cycrimine, biperiden, others) Antidepressants (e.g., SSRIs, SNRIs, TCAs, MAOIs, others) – depression in Parkinson's disease Atypical antipsychotics (e.g., clozapine, quetiapine) – Parkinson's disease psychosis Hypnotics (e.g., eszopiclone, melatonin – insomnia in Parkinson's disease Memantine (Namenda) – cognitive impairment in Parkinson's disease Serotonergic psychedelics (e.g., psilocybin) Stimulants and related (e.g., methylphenidate, modafinil) – fatigue and apathy in Parkinson's disease Wakefulness-promoting agents (e.g., caffeine, modafinil) – excessive sleepiness in Parkinson's disease

=== From organic halides and cyanide salts === Two salt metathesis reactions are popular for laboratory scale reactions. In the Kolbe nitrile synthesis, alkyl halides undergo nucleophilic aliphatic substitution with alkali metal cyanides. Aryl nitriles are prepared in the Rosenmund-von Braun synthesis. In general, metal cyanides combine with alkyl halides to give a mixture of the nitrile and the isonitrile, although appropriate choice of counterion and temperature can minimize the latter. An alkyl sulfate obviates the problem entirely, particularly in nonaqueous conditions (the Pelouze synthesis). In the Kolbe nitrile synthesis (a nucleophilic substitution reaction), an alkanonitrile and an alkali halide are formed from a reactive halocarbons and an alkali cyanide (sodium cyanide or potassium cyanide). The reaction is particularly suitable for primary, allylic, and benzylic halides. Secondary alkyl halides provide lower yields, whereas tertiary halides undergo exclusively elimination reaction instead of substitution. In addition to halides, substrates bearing other good leaving groups may also be employed. In contrast to alkali cyanides, silver cyanide is unsuitable for nitrile synthesis, as it preferentially forms isonitriles. An example of the Kolbe nitrile synthesis is the reaction of methyl iodide with sodium cyanide to yield acetonitrile and sodium iodide:

=== Powder === Powder is either the pure drug by itself (talcum powder), or is made of the drug mixed in a carrier such as corn starch or corn cob powder (Zeosorb AF – miconazole powder). Can be used as an inhaled topical (cocaine powder used in nasal surgery).

Sources: en.wikipedia.org

Further detail

== History == BRT Laboratories, Inc., with its parent company Baltimore RH Typing Laboratory, has been a provider of products and services to the medical, research, and commercial communities since 1945. In April 2000, BRT Laboratories, Inc. was established as an independent and wholly owned subsidiary of Baltimore Rh Typing Laboratory, Inc., for the purpose of continuing commercial testing and service activities.

== Examples == The diabetic drug Liraglutide, incorporates a lipid chain to extend plasma circulation and prolong bio-availability. Liraglutide is a GLP-1 agonist drug that self-assembles into an alpha-helical structure, and it requires once a day administration. Lipid conjugation of a palmitoyl chain to a lysine residue at position 26 of Liraglutide results in an extended half-life (around 13–14 hours) in the blood. This is due to the palmitoyl chain allowing non covalent binding to albumin, which delays proteolytic attack by DPP IV and also rapid renal clearance. Furthermore, the addition of the lipid chain could further prolong half-life by sterically hindering the DPP IV enzyme from degradation. Another peptide known to self-assemble is the octapeptide Lanreotide. This compound is a synthetic analogue of the peptide hormone somatostatin and it is used to treat acromegaly (a condition where the body produced too much growth hormone). In water, Lanreotide self-assembles into monodisperse liquid crystalline nanotubes. The nanotubes are made up of dimers that self-assemble into a 2D crystal, which is held together by lateral chain interactions, and also by anti-parallel ß-sheets. Further insight into how self-assembly and peptide hormones are related has been provided by studies on self-assembling amyloid structures formed by peptide hormones and neuropeptides. Peptide hormones and neuropeptides form dense-cored aggregates that pack into dense-core vesicles (DCVs), which are used to temporarily store peptide messengers in secretory cells.

=== Surgery === When atherosclerosis has become severe and caused irreversible ischemia, such as tissue loss in the case of peripheral artery disease, surgery may be indicated. Vascular bypass surgery can re-establish flow around the diseased segment of the artery, and angioplasty with or without stenting can reopen narrowed arteries and improve blood flow. Coronary artery bypass grafting without manipulation of the ascending aorta has demonstrated reduced rates of postoperative stroke and mortality compared to traditional on-pump coronary revascularization. Atherectomy, which involves the removal of plaques instead of pushing them into the vessel wall, is a minimally invasive alternative to angioplasty.

== Signs and symptoms == Early symptoms are malaise and lethargy. After one to three months, patients develop shortness of breath and bone pain. Myalgias may occur because of reduced carnitine production. Other symptoms include skin changes with roughness, easy bruising, and petechiae, gum disease, loosening of teeth, poor wound healing, and emotional changes (which may appear before any physical changes). Dry mouth and dry eyes similar to Sjögren's syndrome may occur. In the late stages, jaundice, generalised edema, oliguria, neuropathy, fever, convulsions, and eventual death are frequently seen. Signs of scurvy also include hypotension, pulmonary hypertension, and an enlarged heart.

==== Dislocation and subluxation management ==== When a dislocation or subluxation occurs, muscle spasms and stress tend to follow, increasing pain and reducing the chances of the dislocation/subluxation naturally relieving. Methods to support a joint after such an incident include the usage of a sling to hold the joint in place and allow it to relax. Orthopedic casts are not advised, as there could be pain if unrelaxed muscles are still trying to spasm out against the cast. Other solutions to promote relaxation are heat, gentle massaging, and mental distractions.

Sources: en.wikipedia.org

Frequently asked questions

Is semax an approved medicine?

It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.

How is semax usually given in studies?

Most published work uses intranasal administration, matching the route of the registered Russian formulation. Some animal experiments use intravenous or intraperitoneal injection. The route matters because the intact peptide is cleared rapidly from blood, so exposure differs between methods.

What does a purity figure actually tell a buyer?

A purity value describes the share of the powder accounted for by the target peptide, usually by high-performance liquid chromatography. It does not confirm that the sequence is correct, which requires mass spectrometry or amino acid analysis. Purity and identity are separate checks.

Semax 是天然存在的物质吗?

不是。Semax 是完全人工合成的七肽,自然界中没有对应的已知肽段。它的设计灵感来自促肾上腺皮质激素片段 ACTH(4-10),但序列经过了替换和延长。

Network